Proteasomes are multisubunit, energy-dependent, proteolytic complexes that play an essential role in intracellular protein turnover. They are present in eukaryotes, archaea, and in some actinobacteria species. Inhibition of proteasome activity has emerged as a powerful strategy for anticancer therapy and three drugs have been approved for treatment of multiple myeloma. These compounds react covalently with a threonine residue located in the active site of a proteasome subunit to block protein degradation. Proteasomes in pathogenic organisms such as Mycobacterium tuberculosis and Plasmodium falciparum also have a nucleophilic threonine residue in the proteasome active site and are therefore sensitive to these anticancer drugs. This review summarizes efforts to validate the proteasome in pathogenic organisms as a therapeutic target. We describe several strategies that have been used to develop inhibitors with increased potency and selectivity for the pathogen proteasome relative to the human proteasome. In addition, we highlight a cell-based chemical screening approach that identified a potent, allosteric inhibitor of proteasomes found in Leishmania and Trypanosoma species. Finally, we discuss the development of proteasome inhibitors as anti-infective agents.
Introduction
The proteasome is a large multisubunit protein complex that regulates numerous cellular functions, including normal protein turnover and degradation of misfolded proteins. It is generally located in the cytoplasm and nucleus of cells [1] . In eukaryotes, proteins destined for degradation, are first conjugated with one or more ubiquitin chains through the side chain of lysine residues [2], whereas bacterial proteins are conjugated with a prokaryotic ubiquitin-like protein (pup) [3] . These ubiquitinated/pupylated proteins are then recognized and unfolded by regulatory proteins that flank the proteolytic core of the proteasome. Once the protein substrate has engaged the proteasome, the ubiquitin and pup chains are removed by deubiqutinases and depupylases, respectively [4, 5] . The unfolded protein substrates are threaded into the barrel-shaped proteolytic core and degraded into short peptide sequences while the released ubiquitin and pup tags are used to label new substrates. The core of the proteasome is formed by two stacked rings of seven b subunits sandwiched between two rings of a subunits. This 28-subunit complex is commonly referred to as the 20S proteasome while the combination of the 20S core and regulatory proteins is referred to as the 26S proteasome. The 20S complex in bacteria is composed of either one a-and one b-type subunit (e.g., Thermoplasma acidophilum) or two a-and two b-type subunits (e.g., Rhodococcus erythropolis) [6, 7] . In eukaryotes, each subunit of the ring is encoded by a separate gene and therefore consists of seven a-and seven b-type subunits [8] (Fig. 1) .
The subunits responsible for peptide hydrolysis are located in the b-ring. The 14 b subunits of the bacterial proteases are enzymatically active and have broad specificity, however, in eukaryotes, only b1, b2, and b5 subunits have hydrolytic activity. Each b subunit has a distinct substrate specificity profile. For example, b1 in the mammalian proteasome has a preference for cleaving on the carboxyl terminal side of acidic residues and therefore substrates that were originally developed for caspases are hydrolyzed efficiently. Thus, the b1 activity is commonly referred to as 'caspase-like' [9] . In the same manner, the b2 and b5 subunits are referred to as 'trypsin-like' and 'chymotrypsin-like', respectively. The most commonly used fluorescent peptidyl substrates to detect activity by these subunits are z-LLE-AMC for b1, z-LRR-AMC for b2, and suc-LLVY-AMC for b5, where AMC corresponds to the fluorophore, 7-amino-4-methylcoumarin (AMC). In general, natural substrates of the proteasome are longer than the fluorescent substrates and, therefore, will have extended substrate-binding interactions with neighboring b-subunits. For example, a protein that is cleaved by the b5 subunit may interact with b4, b5, and b6 during substrate hydrolysis. A commonly used inhibitor of proteasome activity is MG-132, which consists of z-LLL-al where al corresponds to an electrophilic aldehyde that reacts with the nucleophilic threonine residue in the active site of the proteasome subunits ( Fig. 2A) . MG-132 preferentially inhibits the b5 subunit in the low nanomolar range and the b1 and b2 subunits in the low micromolar range [10] . Between 1999 and 2012, MG-132 had been used as a research tool in over four thousand scientific studies and was a lead compound for development of several anticancer agents [11] .
In human cells, short peptides generated by proteasome hydrolysis are a source of antigens presented by major histocompatibility complex class I (MHC-I) molecules. The constitutive proteasome 20S (c20S) is expressed in most cell types, however, three additional tissue-specific isoforms are known. Immune cells such as antigen-presenting cells, produce an immunoproteasome20S (i20S) that has alternative catalytic subunits called b1i, b2i, and b5i [12]. These subunits generate peptides for MHC-I that differ from those generated by the constitutive proteasome [13] . The thymoproteasome 20S (t20S), contains b1i, b2i, and a b5t subunit that is expressed only in cortical thymic epithelial cells [14] . Finally the spermatoproteasome, expressed in spermatids and mature sperm, is similar to the immunoproteasome except for an alternate a4s subunit [15] . Much attention has focused on the constitutive proteasome when it was revealed that rapidly growing cancer cells were more sensitive to proteasome inhibitors than noncancerous cells [16] . The cytotoxicity of proteasome inhibitors involves multiple mechanisms that include, inhibition of nuclear factor kappa B (NF-kB) activation, stabilization of cell-cycle regulatory proteins, blocking of cell-cycle progression at G2-M phase, and induction of apoptosis [17, 18] . This cytotoxicity formed the basis for development of the drugs, bortezomib (PS-341), carfilzomib (PR-171), and ixazomib (MLN9708) to treat multiple myeloma.
Bortezomib is a dipeptide boronic acid inhibitor that reversibly binds to a nucleophilic threonine residue in Fig. 1 . Schematic representation of a 20S proteasome. The 20S proteasome consists of two outer rings of alpha subunits and two inner rings of beta subunits. The catalytic subunits are located in the beta ring. In prokaryotes such as Mycobacterium tuberculosis all beta subunits are identical and are catalytically active, as indicated by the square substrate-binding pocket. In eukaryotes, only the b1, b2, and b5 subunits are active and the differences in substrate specificity are illustrated by the dissimilar shapes of the substrate-binding pockets. The substrate specificity of the prokaryotic proteasome is most similar to the b5 specificity of the eukaryotic proteasome.
the active site of the b5 and b5i subunits [19] (Fig. 2B) . In 2003, it was approved for intravenous treatment of relapsed or refractory myeloma and eventually as a first-line therapy for patients with multiple myeloma and mantle cell lymphoma. Carfilzomib is an epoxyketone tetrapeptide inhibitor developed from the scaffold of epoxomicin, a natural product isolated from Actinomycetes [20] (Fig. 2C) . Unlike the boronic acid inhibitors, epoxyketones are irreversible and highly selective for the proteasome. Carfilzomib has demonstrated activity against bortezomib-resistant cell lines [21] and was approved in 2012 for treatment of multiple myeloma patients who had previously received bortezomib. Ixazomib, an orally bioactive dipeptide boronic acid inhibitor with improved pharmacokinetics, pharmacodynamics, and antitumor activity over bortezomib, was approved in 2015 [22] . Ixazomib is a prodrug consisting of a protected cyclic boron that is hydrolyzed to the boronic acid, MLN2238 in plasma and other aqueous solutions (Fig. 2D) . Each of these drugs preferentially targets the chymotrypsin-type activity of the constitutive (b5) and immunoproteasome (b5i), however, coinhibition of b1/b1i or b2/b2i occurs at a higher concentration [23] [24] [25] .
Pathogen genomes encode proteasomes that are structurally and functionally similar to the mammalian complex. Until recently, it was unknown whether inhibitors could be developed that selectively target the parasite proteasome and not the host complex. Several studies have used the approved drugs, bortezomib and carfilzomib, to evaluate whether the parasite proteasome is a possible drug target, however, these studies were performed in culture, and toxicity to host cells was not addressed [26] [27] [28] . Pharmaceutical companies continue to develop proteasome inhibitors as anticancer drugs and more recently to target auto-immune disease [29] . As the number of synthetic compounds increase, the likelihood of discovering analogs with selectivity for a parasite proteasome also rises. Collaborations between pharmaceutical companies and academic researchers studying Mycobacterium tuberculosis (Mtb) and Plasmodium falciparum, have identified selective inhibitors of the pathogen proteasome that are analogs of bortezomib [30] and carfilzomib [26] , respectively. In addition, cell-based screening of diverse chemical scaffolds and rational design of inhibitors based on substrate specificity information, have yielded potent compounds with high selectivity for It is a potent and selective inhibitor of the b5 subunit but will also target the b1 and b2 subunits at high concentration. This selectivity is represented as b5 > b1 > b2 and the electrophilic aldehyde group is highlighted in red. (B) Structure of bortezomib, also known as PS-341, with the boronic acid reactive group in red. Bortezomib was the first proteasome inhibitor to be approved as an anticancer agent. (C) Structure of carfilzomib, also known as PR-171 that selectively targets the b5 and b5i subunits of the constitutive proteasome and immunoproteasomes, respectively. The epoxyketone reactive group is highlighted in red. (D) Structure of the prodrug ixazomib that is hydrolyzed in aqueous solution to the active boronic acid inhibitor MLN2238. Among proteasome inhibitors, ixazomib is the first oral compound to be approved for the treatment of multiple myeloma.
proteasomes of parasitic species and low toxicity to mammalian cells. In this review, we focus on studies in which proteasome inhibitors have been evaluated in cell-based assays containing bacteria, protozoa, or helminths that cause disease in humans and other mammals. In addition, we summarize the inhibitor development strategies that have been utilized to develop potent and selective antagonists of parasite proteasomes.
Bacterial pathogens
Mycobacterium tuberculosis, the causative agent of tuberculosis, is responsible for 1.5 million deaths per year [31] . Mtb is an intracellular pathogen that is phagocytosed by alveolar macrophages in the lung after being inhaled. It resides in macrophages, resisting innate defense mechanisms. Infected cells can migrate across the alveolar epithelium into the lung tissue and aggregate to form granulomas [32] . If Mtb overcomes the immune system defense, it can multiply and cause the disease soon after primary infection. One third of the world population maintains a latent form of Mtb infection that will produce an active infection in~5% of the cases. In recent years, the Mtb epidemic has been aggravated by the emergence of drug-resistant strains [33] . Therefore, new drug therapies are badly needed.
Mycobacterium tuberculosis is the only known bacterial pathogen to possess a proteasome, the activity of which is required for Mtb to persist in mice [34, 35] . When Mtb is cultured in stress conditions that mimic the acidic (≤ pH.5.5) and nitrosative environment of macrophages, cells are rendered nonreplicating and sensitive to proteasome inhibitors [36] . Mycobacterium tuberculosis failed to recover from nitritemediated injury when treated with either epoxomicin (Fig. 3A) or a boronic inhibitor, MLN-273 (Fig. 3B ). MLN-273 was developed as a tool to study the mechanism of inhibition of the bacterial proteasome isolated from R. erythropolis [37] and was subsequently found to inhibit Mtb 20S proteasome (Mtb20S) with a half maximal inhibitory concentration (IC 50 ) of 1.6 nM [38] . A crystal structure of MLN-273 bound to Mtb20S revealed the mechanism of inhibition [39] . Studies by the same group determined that bortezomib inhibits the b-subunits of Mtb20S with an IC 50 value of 300 nM, which is 19-fold less potent when compared to the human b5. Using substrate specificity information, substitution of an m-chloro-phenylalanine for leucine in the P1 position of bortezomib reversed the species specificity. The resulting compound, BTZ-16 (Fig. 3C ), was eightfold more selective for Mtb20S [30] . These substrate and inhibitor specificity studies determined that there is a sufficient difference between the pathogen and host proteasomes to develop compounds with greater selectivity for Mtb proteasome.
Using the chymotrypsin substrate, Suc-LLVY-AMC, several plant-derived natural products were found to inhibit Mtb20S with IC 50 values in the range of 25-120 lM [40] . In addition, two covalent inhibitors, GL5 (Fig. 3D ) and HT1171 (Fig. 3E) were discovered in a screen of 20 000 compounds [41] . These oxathiazol-2-one compounds had more than 1000-fold selectivity for Mtb20S over human b5 and were found to irreversibly inhibit the proteasome by cyclocarbonylating the active site threonine. This reaction mechanism shares common features with serine b-lactamases inhibition by O-aryloxycarbonyl hydroxamates and therefore several b-lactamase inhibitors were also found to be potent inhibitors of Mtb20S [42] . GL5 and HT1171 kill nonreplicating Mtb in a dose-dependent manner from 12.5 to 50 lM with no toxicity to mammalian cells up to 75 lM. However, they had poor stability in serum and were found to potently inhibit human b5i [43] .
Peptide aldehydes, such as MG-132, are generally poor inhibitors of Mtb20S [38] but are potent against the mammalian enzymes (K i < 25 nM). However, a lipopeptide aldehyde known as fellutamide B (Fig. 3F ) from the marine fungus, Penicillium fellutanum, is a potent inhibitor of Mtb20S with a K i < 10 nM [44] . The alkyl tail likely increases affinity for Mtb20S when compared to short peptide aldehydes. Fellutamide B is also a potent human proteasome inhibitor and therefore insufficient selectivity exists for it to be developed as an antimicrobial compound. Structural studies with this molecule indicated that selectivity may be achieved by substitution of a branched and shorter alkyl tail on the amino terminus as this may interfere with binding to human proteasome while maintaining potency for Mtb20S [44] .
Finally, screening of Mtb20S with 1600 dipeptides containing varying amino-and carboxyl-termini caps identified a reversible inhibitor, DPLG-2 (Fig. 3G) , with a K i of 15 nM and > 3600-fold selectivity over human b5 and b5i [45] . This compound was stable in human plasma for more than 22 h and killed nonreplicating Mtb in a dose-dependent manner. Targeting of the proteasome by DPLG-2 was confirmed using a competition assay with the irreversible inhibitor, HT1171. However, DPLG-2 was rapidly cleared in mice, and the compound was undetectable in animals after 10 min (personal communication with Gang Lin).
These studies highlight that specificity differences exist between the proteasomes of Mtb and its obligate human host and that clear progress has been made to develop compounds with increased potency and selectively for the Mtb proteasome. Computational screening of drug-like molecules has yielded several noncovalent compounds that are promising drug candidates [46] . However, a major hurdle in evaluating these inhibitors is the lack of animal models that faithfully mimic the Mtb persistence that occurs in humans [47] .
Protozoan parasites
Parasitic protozoa are unicellular eukaryotic organisms with varied and complex life cycles, comprising multiple differentiation events, physical environments and hosts. These organisms are the causative agents of several human diseases that when combined, cause more than a million deaths annually [48] . The ubiquitinproteasome system from pathogenic protozoa has been reviewed in detail previously [49, 50] ; therefore, this section will focus on inhibitor development efforts for kinetoplastid, apicomplexa, and amoeba parasites.
Kinetoplastid
Three kinetoplastid diseases, leishmaniasis, African sleeping sickness, and Chagas' disease are caused by Leishmania species, Trypanosoma brucei, and Trypanosoma cruzi, respectively. Together, they affect million people among the world's poorest populations, causing high morbidity and leading to more than 50 000 deaths annually [51] . There is a dire need for drug development to control these diseases, mainly because of the emergence of drug resistance and side effects associated with the current therapies [52] .
The proteasome was suggested as a drug target for Trypanosoma and Leishmania when treatment with proteasome inhibitors showed changes in cell growth and development. Specifically, lactacystin (Fig. 4A ) and MG-132 ( Fig. 2A) prevented the transformation of T. cruzi from trypomastigotes into amastigotes in a concentration-dependent manner [53] . The purified proteasome from bloodstream and procyclic T. brucei forms was sensitive to several proteasome inhibitors including lactacystin with IC 50 of 1 lM. In addition, proliferation of bloodstream and procyclic T. brucei was blocked by lactacystin at concentrations > 5 lM [54] . In vitro assays using different Leishmania species produced similar results. Promastigotes of Leishmania donovani incubated with 2 lM MG-132 for 72 h or 5 lM for 24 h resulted in 50% and 95% cell death, respectively [55] . Surviving cells were shorter with rounded apical ends and had DNA and mitochondrial damage. After 6 days of treatment of Leishmania chagasi with 50 lM lactacystin, a 10-fold reduction in viable cells was recorded; while exposure of promastigotes to lactacystin prior to infection of macrophages decreased survival in the host cell by 98% [56] . Proteins essential to cell cycle were identified as proteasome substrates in these parasites [57, 58] . Taken together, these studies reveal the importance of proteasome activity in kinetoplastid parasites.
In a high-throughput phenotypic study performed at the Genomics Institute of the Novartis Research Foundation (GNF), a compound termed GNF5343 (Fig. 4B ) was identified as a hit in proliferation assays of L. donovani and T. brucei with half maximal effective concentration (EC 50 ) values of 7.3 and 0.15 lM, respectively. This hit was optimized to improve bioavailability and potency against L. donovani resulting in a compound with 400-fold increase in potency (EC 50 = 18 nM). This compound, GNF6702 (Fig. 4C) , was also potent against T. brucei and T. cruzi cultures, with EC 50 values of 70 and 120 nM, respectively [59] . Trypanosoma cruzi was cultured in the presence of increasing concentration of GNF6702 analogs and two resistant clones were isolated and analyzed by wholegenome sequencing. The proteasome was found to be the molecular target of these compounds. This target was subsequently confirmed by the accumulation of ubiquitinylated protein following the incubation of T. cruzi with the inhibitor. GNF6702 inhibits b5 activity in an unusual noncompetitive manner. It does not interact with the threonine residue in the b5 subunits but binds to the b4 subunit at a site near the b4-b5 interface. Mutagenesis studies confirmed that Phe24 and Ile29 in the b4 subunits were important for binding. These residues are conserved in L. donovani, T. cruzi, and T. brucei but absent in the b4 subunit of human proteasomes. In fact, the b4 subunit of the drug-resistant T. cruzi line and the human proteasomes have methionine at position 29. Consequently, GNF6702 does not inhibit the human proteasome and no accumulation of ubiquitinylated proteins was detected in mouse fibroblast cells following treatment.
Using an oral dosing scheme of 10 mgÁkg À1 twice daily, parasite burden in liver of mice infected with L. donovani was reduced by more than 99.8% after 8 days of treatment. In addition, treatment for 7 days resulted in a fivefold decrease in parasite burden in footpads of mice infected with the dermatotrophic Leishmania major strain. In a mouse model of Chagas disease, 20 days of treatment with GNF6702 was sufficient to reduce T. cruzi levels in blood, heart, and colon to undetectable levels while 100 mgÁmL À1 treatment once daily with the same compound eliminated T. brucei in brains of mice modeling stage II sleeping sickness [59] .
Apicomplexa
The proteasome in P. falciparum has been validated as a therapeutic target following effective killing of the parasite at various life stages [60] using lactacystin [61, 62] , marizomib [63] , bortezomib [27] , MLN-273 [64] , MG-132 [62] , epoxomicin [62] , and carfilzomib [26] . These compounds are generally toxic to mammalian cells, however, MG-132 was found to have more than 225-fold higher selectivity for P. falciparum relative to human peripheral blood mononuclear cells [62] . This selectivity was due to its promiscuous inhibition of both the proteasome and the hemoglobindegrading cysteine proteases. While MG-132 presented an opportunity to develop dual-target inhibitors of malaria parasites, much of the subsequent screening approaches focused solely on proteasome inhibitors that are selective for the Plasmodium proteasome active sites. A library of 670 carfilzomib analogs was screened in a 72 h P. falciparum replication assay and a parasiteselective compound called PR3 (Fig. 5A) was identified. PR3 was 100-fold less potent than carfilzomib against the trophozoite stage but had no toxicity on human fibroblasts up to 50 lM [26] . PR3 was found to preferentially target the b5 subunit of the Plasmodium proteasome and treatment of Plasmodium bergheiinfected mice with 80 mgÁkg À1 of inhibitor resulted in a moderate but significant reduction in parasite burden during the treatment period. This is the first demonstration that the Plasmodium proteasome could be selectively targeted with low host toxicity. In another study, 1600 noncovalent, N,C-capped peptidic proteasome inhibitors were screened in an in vitro assay using purified P. falciparum 20S proteasome (Pf20S) and the proteasome b5-selective fluorescent substrate, Suc-LLVY-AMC [65] . This library was similar to the set of compounds that was used to identify DPLG-2 (Fig. 3G) as a potent and selective inhibitor of Mtb20S proteasome [45] . Nine compounds were identified that had selectivity for Pf20S relative to the human constitutive proteasome. A common feature of the hit compounds was a 4-methylbenzyl group in the P1 position and a bulky homo-phenylalanine in the P3 position. One compound, cyclic peptide 1 (Fig. 5B) , had more than 1450-fold selectivity for P. falciparum relative to human fibroblasts after 72 h. This selectivity was due to coinhibition of the b5 and b2 subunits of Plasmodium while only the b5 of the human proteasome was targeted [65] . Although dual inhibition of b2 and b5 is lethal to Plasmodium viability, pulse inhibition of the mammalian b5 proteasome alone does not result in significant toxicity in most nontransformed cells [66] . In a separate study, a combination treatment of P. berghei-infected mice with 50 mgÁkg À1 of a b5 inhibitor, PR709A (Fig. 5C ), and 20 mgÁkg À1 of a b2 inhibitor, LU102 (Fig. 5D ), was more effective than treatment with either inhibitor alone [67] . Taken together, these studies suggest that targeting the b5 subunit along with b1 and/or b2 of the Plasmodium proteasome may be key for developing potent and selective antimalarial compounds. In a follow-up study, the Plasmodium and constitutive human proteasomes were incubated with a library of diverse synthetic peptides [68] , to identify sequences that are preferentially cleaved by each proteasome. Cleavage of bonds within these peptides was detected using liquid chromatography-tandem mass spectrometry (LC-MS/MS) sequencing. Using this approach, the Plasmodium proteasome had a clear preference for tryptophan in the P3 and P1 positions when compared with the human constitutive proteasome [69] . Using a tri-leucine-vinyl sulfone (vs) inhibitor as a starting scaffold [70] , peptide-vs consisting of tryptophan at P3 or P1 were synthesized. Two compounds, WLL-vs (Fig. 5E ) and WLW-vs (Fig. 5F ) targeted the b2 subunit, however, WLL-vs also reacted with the b5 subunit. After a 1-h incubation period, WLL-vs potently inhibited P. falciparum with 675-fold selectivity over human fibroblasts. This selectivity was due to preferentially targets the Pf20S b5 over b2 while also targeting the b5 of c20S more than b1 (Pf20S b5 > b2; c20S b5 > b1). (B) Cyclic peptide 1 was discovered in a screen of noncovalent, N,C-capped proteasome inhibitors. (C) PR709A was found to be a selective inhibitor of Pf20S b5 and (D) LU102 is selective for the b2 subunits of Pf20S and human c20S. (E) WLL-vs was designed from substrate specificity differences between the Pf20S and c20S proteasomes and coinhibits Pf20S b5 and b2. (F) WLW-vs inhibits Pf20S b2 and synergizes with DHA to kill artemisininresistant strains of Plasmodium.
inhibition of both the b5 and b2 subunits of Pf20S while only the b5 of the human complex was targeted. Subsequently, a single bolus dose of 35 mgÁkg À1 WLL-vs was administered to Plasmodium chabaudiinfected mice that resulted in almost a complete reduction of parasite burden without toxicity to the host.
Artemisinin derivatives are the first-line drugs used to treat malaria. Resistance to these drugs has emerged in Southeast Asia, resulting in a dire need for alternative treatments [71] . In a study by Tilley and colleagues, cotreatment of P. falciparum with dihydroartemisinin (DHA) and either epoxomicin, carfilzomib, or bortezomib resulted in strong synergistic killing of both DHA-sensitive and DHA-resistant strains. DHAresistant parasites have an enhanced cell stress response and therefore are hypersensitive to proteasome inhibitors [28] . Epoxomicin, carfilzomib, and bortezomib preferentially target the b5 subunit of Plasmodium and therefore a similar experiment was performed with the b2 subunit inhibitor, WLW-vs. A combined treatment of DHA and sublethal doses of WLW-vs resulted in synergistic killing of a DHA-resistant strain.
In a P. berghei mouse model, cotreatment with 1 mgÁkg À1 of carfilzomib and 5 mgÁkg À1 of DHA significantly reduced parasite burden when compared to treatment with either compound alone [28] . These data suggest that combination therapy of Food and Drug Administration (FDA; USA)-approved multiple myeloma drugs with DHA may have clinical use in treatment of artemisinin-resistant strains. However, the well characterized toxicity of these proteasome inhibitors suggests that more work will need to be done to develop safer drugs that could be administered orally for extended periods. To date, the most selective proteasome inhibitors for Plasmodium have come from in vitro or phenotypic screens of compound libraries or have been rationally designed from substrate specificity information. However, a 3.5 A structure of the Pf20S bound to WLW-vs has now been elucidated by cryo-electron microscopy (cryo-EM) and single particle analysis [69] . When this structure was compared to the cryo-EM structure of the human constitutive proteasome, the basis for WLW-vs specificity was revealed [72] . The Plasmodium b2 ligand-binding pocket accommodates the bulky side chains of tryptophan at the P1 and P3 positions, while the human b2 pocket cannot. In fact, the other substrate-binding pockets of the human proteasome active subunits also have restricted access for bulky side chains at P1 and P3. Therefore, specificity and structural information now serve as powerful tools to rationally design inhibitors with increased potency toward the Plasmodium proteasome and reduced toxicity of the human complex [73] .
Babesia is a tick-transmitted protozoan parasite that infects erythrocytes of several wild and economically valuable animal species causing serious economic losses in the livestock industry. Some Babesia species can infect humans, and human babesiosis is considered an emerging tick-borne zoonotic disease [74] . Available drugs to treat babesiosis in cattle are toxic and the emergence of resistance is likely [75] . The potential of epoxomicin to inhibit parasite growth was tested in several Babesia species [76] . In in vitro cell cultures, epoxomicin showed an IC 50 in the nanomolar range for Babesia bovis, Babesia bigemina, Babesia ovata, Babesia caballi, and Babesia equi. A combination of epoxomicin and diminazene aceturate potentiates the effect on parasitemia and growth inhibition in in vitro cell cultures of B. bovis, B. bigemina, and B. caballi. In vivo assays performed in mice infected with Babesia microti indicate that parasitemia is significantly lower in mice treated with 0.05 mgÁkg À1 or 0.5 mgÁkg À1 epoxomicin for 10 days when compared with control treatment animals. The proteasome was not validated as the molecular target of epoxomicin in this study, however, B. bovis proteasome subunits are expressed during the erythrocyte stage [77] and epoxyketone inhibitors are known to be highly selective for proteasome subunits [78] . Therefore, it is expected that epoxomicin selectively targets the Babesia proteasome.
Amoeba
Entamoeba histolytica, a parasite causing intestinal disease, is transmitted in contaminated water or food from one host to the other in the form of a latent cyst. Excystation occurs in the digestive tract to produce a proliferative trophozoite form that can cause amoebic dysentery or liver abscess [79] . Encystation is key to propagating infection and therefore blocking this step is a therapeutic goal [80] . Exposure of E. histolytica to low micromolar amounts of lactacystin for 3 days, resulted in 73-100% growth inhibition [81] . In addition, lactacystin prevented encystation by the reptile pathogen Entamoeba invadens [82] , which is commonly used as a model for E. histolytica [81, 82] . The proteasome was isolated from E. histolytica and the chymotrypsin-type, trypsin-type, and caspase-type activity were shown to be inhibited by lactacystin. These studies demonstrate that Entamoeba species require proteasome activity for conversion of the disease-causing trophozoite form into the infective cyst form. Acanthamoeba spp. are widespread free-living opportunistic amoeba that cause granulomatous amoebic encephalitis, cutaneous acanthamebiasis, and acanthamoeba keratitis (AK). Treatment of AK infections are difficult due to resistance of the cyst stage to chemical therapies, making encystation a major challenge in the successful treatment of amoebae infections [83] . The ubiquitin-proteasome system and lysosomal proteases are important components of encystation, due to the high levels of protein turnover that occurs during this differentiation stage [84, 85] . In culture, incubation of Acanthamoeba castellanii with micromolar amounts of lactacystin and bortezomib decreased encystation by 30-49% [86] .
Other protozoa
Tritrichomonas foetus is an obligate parasite of the bovine reproductive tract that can cause endometritis, infertility, and early embryonic death [87] . This sexually transmitted disease is responsible for considerable economic losses to the beef and dairy cattle. In addition, T. foetus is a causative agent of chronic diarrhea in domestic cats [88] . Imidazoles have been used to treat cats but are often ineffective [88] . Tritrichomonas foetus exists as a trophozoitic form but can transform into a pseudocyst under nutrient and temperature stress [89] . Incubation of T. foetus cultures with 20 lM lactacystin for 18 h resulted in complete inhibition of growth of the trophozoitic form with a general arrest of cell cycle in the G2-M phase and prevented transformation of the trophozoitic form to the pseudocyst form during coldinduction assays [90] . In another study, gliotoxin, a proteasome inhibitor isolated from fungi [91] , inhibited T. foetus growth at concentrations ≥ 1 lM arresting cell cycle in the G2-M phase and causing DNA fragmentation. When the proteasome was isolated from gliotoxintreated cells, chymotrypsin-like activity was reduced by 48-67% compared to untreated cells [92] .
Helminths

Schistosoma
Schistosomiasis is a tropical water-borne disease caused by the Schistosoma blood fluke that infects over 240 million people [93] . The disease is chronic and painful as a result of numerous pathologies associated with the parasite's eggs that become trapped in various visceral organs. There is no vaccine and treatment of schistosomiasis relies on just one drug, praziquantel [94] [95] [96] [97] . The risk of resistance and the lack of alternative drugs spurs the identification of new drug options. The contribution of the ubiquitin-proteasome system in protein hydrolysis in Schistosoma has been demonstrated in cercariae (infective larvae) and adult worms [98] , and the 20S proteasome was purified, and analyzed by two-dimensional gel electrophoresis/mass spectrometry (2-DE/MS) [99] . Indirect evidence points to the schistosome proteasome as a drug target. Mice exposed to cercariae that had been pre-treated with MG-132, had 65% less migrating lung parasites than control-treated mice [98] . In addition, exposure in vitro of Schistosoma mansoni postinfective larvae (schistosomula) to short-interfering RNAs targeting a deubiquitinase subunit of the 19S regulatory particle, resulted in 78% decrease in parasite viability [100] . Preliminary data from our group using WORMASSAY software [101] , shows that incubation of adult S. mansoni worms with 1 lM of either bortezomib or carfilzomib, results in more than 90% reduction in parasite motility when compared to a dimethyl sulfoxide (DMSO)-treated control (Fig. 6 ).
Cestoda
Alveolar echinococcosis is a rare but often fatal disease in humans caused by metacestode larvae of Echinococcus multilocularis. This tapeworm is more commonly found in dogs, however, rodents act as intermediate hosts. Echinococcus multilocularis causes parasitic tumors in many human organs and are often treated with benzimidazoles [102] . In one study, E. multilocularis metacestodes were incubated with 426 FDA-approved drugs and bortezomib was identified as the most potent drug with EC 50 of 0.6 lM [103] . Metacestode treatment with bortezomib induced serious morphological alterations resembling apoptotic cells at concentrations as low as 50 nM. The proteasome was validated as the molecular target of bortezomib, because accumulation of ubiquitinated proteins was evident. In addition, chymotrypsin-like proteasome activity in cellular lysates was inhibited in a dose-dependent manner. Despite good in vitro efficacy against larvae, bortezomib had poor efficacy in a mouse model of secondary alveolar echinococcosis [103] . However, future improvement of the animal model could lead to a better understanding and validation of proteasome inhibitors in vivo.
Tools and techniques for proteasome inhibitor discovery
For groups involved in research on pathogenic organisms, there are many tools available to evaluate the proteasome as a drug target. The fluorescent substrates, z-LLE-AMC, z-LRR-AMC, and suc-LLVY-AMC appear to be universally applicable for monitoring b1, b2, and b5 activity, respectively, of eukaryotic proteasomes, while suc-LLVY-AMC can be used to evaluate proteasome activity in bacteria. These substrates can be purchased from numerous vendors, however, it should be noted that serine and cysteine proteases in cellular extracts can also cleave these substrates. Therefore, it is essential to include 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF; 1 mM) and E-64 (50 lM) in the lysis buffer prior to performing proteasome activity assays. Proteasome activity in cellular lysates can also be evaluated using activity-based probes that selectively target individual subunits [104] or broad acting probes that target all subunits [67] . Inhibition of proteasome activity in a live cell will result in the accumulation of ubiquitinated proteins which is often visualized as a smear by western blot using anti-ubiquitin antibodies [59, 105] thus confirming on-target efficacy of proteasome inhibitors.
Many of the proteasome inhibitors that have been investigated as anticancer drugs can be purchased from commercial sources, however, the pathogen-specific compounds discussed in this review are not yet offered from vendors. Proteasome inhibitor collections within pharmaceutical companies have been made available to academic groups [26, 45, 65] and it is likely that these collaborations will continue to identify pathogenspecific compounds. While much of the rational design and screening approaches highlighted here has focused on active site inhibitors, it is now clear from research on kinetoplastid organisms, that development of a potent allosteric proteasome inhibitor with minimal host toxicity is possible. The discovery of an antileishmanial and antitrypanosomal compound by GNF in a library of 3 million compounds relied on serendipity and 'brute-force' phenotypic screening. Therefore, this approach may not be successful for identifying proteasome inhibitors in other human pathogens. If structural studies begin to identify allosteric sites in the pathogen proteasome that are absent in the human complex, then rational design of allosteric inhibitors will likely facilitate development of antipathogen compounds that are safe in humans.
X-ray crystallography has revealed the atomic structures of bacterial [39] and mammalian 20S proteasomes bound to inhibitors [106, 107] . However, for many pathogens, it can be difficult and often impractical to isolate sufficient proteasome at high purity for crystallography studies. Cryo-EM and single particle analysis have recently been used to determine highresolution protein structures of human [108] and malarial [69, 72] proteasomes with peptide inhibitors bound in an active site. Cryo-EM generally requires less protein than X-ray crystallography and is more suited to large stable complexes [109] . In addition, the experimental conditions used in cryo-EM are likely to better reflect the physiological environment of proteinligand interactions. Structural information for pathogen proteasomes will guide future drug design, and we and others [72] anticipate that high-resolution cryo-EM will be a method of choice.
Conclusion
There is an urgent need for new and more effective drugs to treat parasitic diseases. Many of the diseases discussed in this review affect people, often children, in the developing world. Therefore, safe and cost-effective drugs are an essential requirement for drug discovery efforts. Proteases have long been considered as excellent drug targets [110] and protease inhibitors have been used extensively to treat human immunodeficiency virus (HIV) and hepatitis C virus (HCV) [111, 112] , type 2 diabetes [113] , cardiovascular diseases [114] , and more recently cancer [115, 116] . Until recently it was unknown whether a proteasome inhibitor targeting a pathogenic organism could be administered orally and have low toxicity in the mammalian host. In this review, we have highlighted an allosteric inhibitor of kinetoplastid proteasomes that has unprecedented in vivo efficacy for clearing parasites following oral administration. This inhibitor is tolerated in mice at daily doses of up to 100 mgÁkg À1 and is currently undergoing preclinical toxicity studies [59] . For covalent inhibitors, oral dosing of a peptide-vs prevents cardiac damage in dogs due to infection with T. cruzi [117] . In this case, the protease inhibitor, K777, targets a cysteine protease rather than the proteasome in T. cruzi [118] but confirms that oral formulation for this class of compound is possible. The antimalarial compound, WLL-vs, is chemically similar to K777 and studies are ongoing to improve potency and oral bioavailability of WLL-vs [69] . A second generation oral inhibitor of human proteasomes is now an approved drug for treatment of multiple myeloma [119] . This compound, ixazomib, is delivered as a prodrug and is hydrolyzed to the biologically active peptide boronic acid form upon exposure to plasma. In addition, an oral bioavailable peptide epoxyketone, oprozomib, is currently in Phase 1b studies for treatment of multiple myeloma [120] . Taken together, these studies reveal that inhibitors targeting the active sites or allosteric sites in the proteasome can be designed to have good oral bioavailability and low toxicity toward the mammalian host. Therefore, proteasome inhibitors offer promise as next-generation antiparasitic agents.
